However, the past 2 decades have witnessed the emergence of an expanded and effective risk stratification model, resulting in more reliable identification of those patients at increased SD risk, who may become candidates for the life-saving benefits of implantable cardioverter-defibrillators (ICDs), 1, 9, 11, 13, [19] [20] [21] [22] [23] [24] [25] [26] [27] and advancements in heart transplantation, modern resuscitation techniques, and surgical management of outflow tract obstruction, as well. [9] [10] [11] [12] [13] 23, 23, [28] [29] [30] [31] Whether these contemporary management options have resulted in reduced mortality rates for children and young adults with HCM is currently unresolved, and is the subject of the present clinical outcome investigation.
I n hypertrophic cardiomyopathy (HCM) youthful age has historically been considered the period of life most commonly associated with premature death attributable to adverse disease consequences, in particular, the risk for unexpected sudden death (SD). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The diagnosis of HCM in young patients continues to be accompanied by grim or unfavorable predictions of reduced life expectancy and limited effective treatment options.
Risk Stratification
SD risk stratification was performed by using the conventional markers according to the algorithm advanced in the United States/Canada (American College of Cardiology/American Heart Association) consensus guideline panels and current practice, for the purpose of prospectively identifying high-risk HCM patients who may benefit from prophylactic ICD therapy, 1,2,9-13,19-22,28,35-40 ie, ≥1 major risk factors within the clinical profile of an individual HCM patient within the context of shared decision making with a fully informed patient. Major conventional risk factors 1, [9] [10] [11] [12] [13] 19, 20, 22, 23, [37] [38] [39] [40] used in these assessments are: (1) family history of SD attributable to HCM in ≥1 first-or second-degree relatives; (2) unexplained recent syncope; (3) massive LV hypertrophy (wall thickness ≥30 mm), (4) multiple repetitive nonsustained ventricular tachycardia on ambulatory (Holter) ECG monitoring; (5) hypotensive or blunted blood pressure response to exercise, although the latter 2 markers have proven less applicable to patients <18 years of age. 1 For comparison, a retrospective assessment of SD risk was performed in the present cohort by using the European Society of Cardiology mathematical SD risk model and score. 41, 42 
Imaging
Transthoracic echocardiographic studies were performed in a standard fashion. LV wall thickness was the maximum end-diastolic dimension within the chamber (usually ventricular septum). Peak instantaneous LV outflow gradient was estimated by continuous-wave Doppler and obstruction was defined as a gradient ≥ 30 mm Hg. 35 Cardiovascular magnetic resonance studies were obtained in 179 patients with 1.5 T clinical scans. Cine sequences were performed in standard views with full LV coverage. Late gadolinium enhancement images were acquired 10 to 15 minutes after intravenous administration of 0.2 mmol/kg gadolinium-diethylenetriamine pentaacetic acid using a breath-held segmented inversion-recovery sequence. Late gadolinium enhancement quantification was performed as previously reported.
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Defibrillators
Single-or dual-chamber ICDs with capacity for antitachycardia and antibradycardia pacing were implanted in 231 patients for primary (n=212) or secondary (n=19) prevention. Stored intracardiac electrograms were analyzed for arrhythmias responsible for defibrillator discharges (shocks or antitachycardia pacing) by expert electrophysiologists at each center, according to previous definitions in HCM studies. 1, 19, 20 Defibrillator discharges were considered appropriate when triggered by ventricular fibrillation or rapid sustained ventricular tachycardia (rate>180/min). Rate cutoffs for arrhythmia detection were programmed, and antitachycardia pacing was activated at the discretion of the managing electrophysiologists. 
Statistical Analyses
Descriptive Statistics
Survival and Event Analysis
For patients with known survival and event status, the fraction at each follow-up interval was estimated by the Kaplan-Meier method. The expected fraction surviving at each time after the initial visit was computed by assigning the probability of surviving, appropriate to age and sex, based on the US general population. Actual and expected surviving fractions were compared by using 1-sample log-rank test, which also provides an estimate for the standardized mortality ratio and 95% confidence interval. 43 Survival analysis calculations of adverse nonfatal HCM-related events excluded the 16 patients with either resuscitated cardiac arrest or appropriate ICD intervention occurring before initial clinical evaluation at the participating institutions. Computations used version 2.36 of R software systems (Development Core Team 2012).
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prophylactic ICD therapy (a 17-year-old first evaluated with massive LV hypertrophy who died suddenly at age 19; and an 11-year-old with a family history of HCM-related SD in 2 relatives who died suddenly at age 20). Eight other patients did not receive an ICD recommendation either because they were judged to be at low risk without conventional markers (n=3), or died in the 1990s before systematic employment of ICDs for HCM (n=5). The remaining 2 patients died suddenly as a consequence of a mechanical ICD failure at 21 and 45 years. 44 
Major Nonfatal HCM-Related Events
Of the 474 study patients, 63 (13%) experienced adverse but nonfatal HCM-related events, 1.8%/y (in 47 events after initial evaluation), and exceeding by 2-fold (233%) the HCM-related mortality within the cohort (Table 2; Figure 1 ). §Transplant considered in 14 other patients but not performed, most commonly because of comorbidity (n=5); also, because declined or without insurance or currently listed (n=4).
‖Includes sotalol, flecainide, digitalis, spironolactone, clopidogrel, and dofetilide. ¶Includes 3 patients with end-stage heart failure and systolic dysfunction (29) . #Twenty-seven-year-old man taking warfarin with history of atrial fibrillation and 27-year-old woman with hemorrhagic stroke. **Attributable to sinus tachycardia, supraventricular tachycardia, T-wave oversensing, lead malfunction.
† †Lead fracture, dislodgements, or insulation defect without inappropriate shock (n=11); hematoma/thrombosis (n=2); pocket revision (n=2); infection (n=1); generator malfunction or replacement because of manufacturer's advisory or recall (n=1); perforation of right atrium during lead extraction (n=1). 
ICD Interventions
Of the patients with ICDs, 42 (18%) experienced ≥1 appropriate ICD intervention for ventricular tachycardia/ventricular fibrillation (31 primary and 11 secondary prevention); 5-year cumulative probability was 17%. Of these 42 patients, 22 had ≥2 ICD interventions including: ≥5 in 7 patients, and up to 14 in 1 patient; 1 other patient had a ventricular tachycardia-ICD storm with 9 shocks. Each of the 42 patients are currently alive 4.2 (2.5, 7.8 years; and up to 20) after their first appropriate ICD intervention at 29±7 years. Specifically, of the 212 primary prevention ICD implants, 31 (15%) had appropriate interventions over the period of follow-up (5-year probability, 13%). Initial ICD discharge was at 23±7 years of age (range, 9-42) with the interval from implant to first ICD intervention 2.0 (1.0, 5.4 years; range to 13). Therefore, of the 63 nonfatal aborted HCM events, 31 (49%) were interventions from primary prevention ICDs.
Risk Stratification
In the 31 patients with appropriate ICD interventions, the number of risk markers were: 1 (n=16); 2 or 3 (n=15). Individual risk factors were massive LV hypertrophy ≥30 mm (n=18), unexplained syncope (n=11), family history of SD (n=11), and nonsustained ventricular tachycardia on ambulatory (Holter) ECG (n=6).
Applying the European Society of Cardiology risk stratification statistical model and score to our cohort 41 showed that, of the 40 high-risk patients with combined SD and appropriate ICD interventions for primary prevention, 20 (50%) had lowrisk scores of <4%/5 years, regarded by European Society of Cardiology as insufficient to recommend ICDs; and only 11 (27%) had scores >6%/5 years, considered an ICD indication ( Figure 2 ); 6 of these 11 patients already had met conventional criteria with 2 or 3 risk markers warranting implantation.
ICD Complications
Overall, 60 of the 231 ICD patients (26%) experienced ≥1 device-related complication (1.8%/y; Table 1 ). Inappropriate shocks occurring in 42 of the 231 patients (18%) were as frequent for primary (39/212; 19%) as for secondary prevention (3/19; 16%; P=1.0). Notably, of 42 patients experiencing inappropriate shocks, 13 (31%) also had appropriate device interventions.
Advanced Heart Failure/Transplant
Eighteen patients with nonobstructive HCM underwent heart transplantation (at 26±8 years; 11 patients <25 years old) for drug-refractory and unrelenting heart failure symptoms. These 18 included 10 patients with ejection fraction <50%, 7 with ≥50%, 29 and 1 unknown. Fifteen of the 18 patients (83%) survived 10.8 (6.9, 14.8) years; with range to 26, whereas the other 3 patients died of complications following heart transplant after 1.1 (0.9, 1.5) years. In addition, of the 51 patients who underwent surgical septal myectomy to relieve LV outflow obstruction and severe heart failure symptoms, 50 (98%) are alive at ages 27±6 years; with 46 (90%) improved to New York Heart Association classes I/II; 1 other patient died at myectomy.
Cardiac Arrest/Defibrillation
Twenty other patients were resuscitated from out-of-hospital cardiac arrest with timely external defibrillation (and therapeutic hypothermia in 1). In 13 of these 20 patients, events occurred before first visit by 1.1 (10.7, 4.9) years. Each has survived to the end of follow-up, 6.8 (3.9, 11.1) years, including 11 with secondary prevention ICD shocks and 2 with subsequent transplant.
Events Before Initial Evaluation
Sixteen of the 452 surviving patients (3.5%) had either out-ofhospital cardiac arrest (n=8), ICD shock (n=3), or both (n=5), occurring 1.3 (0.6, 4.7) years before the initial hospital visit. Age at the initial event was 19.6±4.9 years (range, 11-29); 56% were male. Of these 16 patients, 11 experienced no further episodes over a follow-up period of 5.7 (2.3, 11.0) years after their initial event. The other 5 patients had appropriate ICD interventions (n=3), or both an ICD shock and later heart transplant (n=2).
Event Rates
HCM-related mortality rate was 0.54%/y ( Figure 3 ). Survival at 5 and 10 years, considering only HCM-related deaths, was 97% (95% CI, 95%-98%) and 94% (95% CI, 90%-97%), respectively, exceeding expected (all-cause) mortality in the age-and sex-matched general US population (standardized mortality ratio: 4.77 [3.01, 7 .58]; log-rank P<0.001 ( Figure 4A ). HCM deaths combined with events aborted by major treatment interventions (n=63; 2.2%/y), exceeded HCM mortality (n=18; 0.54%/y; P<0.001; Figure 4B ).
Multivariate independent predictors of HCM mortality and nonfatal aborted events were younger age at diagnosis, increased left atrial dimension, and greater LV thickness (Table 3) . Advanced New York Heart Association functional class (III/IV) was a significant variable for the outcome end points only in the univariate analysis.
All-cause mortality in HCM patients (n=22; 5%) was 0.66%/y, exceeding that expected in a general age-and sexmatched US population (standardized mortality ratio: 5.83 [3.84, 8 .86]; log rank P<0.001). Survival at 5 and 10 years was 97% (95% CI, 94%-98%) and 94% (95% CI, 90%-96%), respectively.
Discussion
Among the broad HCM disease spectrum, young patients have historically been regarded at the highest risk for adverse disease consequences, particularly unexpected SD, and this perception is confirmed by the present data. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Indeed, the older literature reported an annual HCMmortality risk (largely for SD) of up to 6%/y largely in children, 5-7 based on biased tertiary center referral patterns. 45 The substantial visibility more recently afforded SDs in young competitive athletes, attributable to HCM, has contributed to this perception of a generally high-risk disease. Figure 1 . Diagram summarizing clinical outcome in 474 individual children, adolescents, and young adult HCM patients 7 to 29 years of age at study entry. Symbols: *16 events occurred before the first evaluation by 1.3 (0.6, 4.7) years; range, 3 days to 11.4 years, including 13 resuscitated out-of-hospital cardiac arrests and 3 appropriate ICD interventions. **Includes: out-of-hospital resuscitated cardiac arrest (RCA; n=9); RCA followed by appropriate secondary prevention ICD interventions (n=9); RCA with subsequent appropriate secondary prevention ICD interventions, and followed by transplant (n=2). †Died 0.9, 1.1, and 1.5 years after transplant. ‡Includes 1 patient with heart transplant, 4 months after ICD intervention. ΔRhabdomyolysis and liver failure secondary to statin therapy, died awaiting transplant (n=1); automobile accident (n=1). HCM indicates hypertrophic cardiomyopathy; and ICD, implantable cardioverter-defibrillator.
by guest on May 23, 2017 http://circ.ahajournals.org/ Downloaded from subsequent clinical course with low SD event rate (0.2%/y), even in the presence of risk factors, and less than expected in the US general population of the same age and sex. 48 In the present cohort study, we have expanded our observations on age and HCM outcome by longitudinally tracking clinical course and the impact of major treatment initiatives on the youngest affected patients <30 years of age presenting to 2 major tertiary referral institutions. Among almost 500 patients, aged 7 to 29 years at presentation, we found that even in this clinically identified and potentially vulnerable population (including some patients with aggressive early-onset disease) HCM-related mortality was relatively low at 0.5%/y. Indeed, this mortality rate was predominantly attributable to the termination of potentially lethal arrhythmic events by prophylactically implanted ICDs, and heart transplants in patients with refractory and irreversible heart failure, as well.
In addition, several patients survived out-of-hospital cardiac arrest with modern defibrillation techniques. This subset provides a window to, but undoubtedly underestimates, HCMrelated events that may occur before clinical recognition in nonresuscitated patients. Such patients would consequently not appear in the present data set, underscoring that HCM is at highest risk in young patients. In the present study, patients who survived cardiac arrest are included in the clinical and demographic analysis, but not in the survival assessment. Importantly, our cohort patients surviving potentially lethal disease consequences by virtue of major treatment interventions exceeded by 3-fold the actual HCM deaths (1.8%/y versus 0.54%/y).
There are 42 patients in the present study (9%) who have survived to the end of follow-up based on the decision to implant an ICD for primary (or secondary) prevention using currently proven risk stratification strategies that are part of the United States/Canada (American College of Cardiology/American Heart Association) guidelines for HCM [9] [10] [11] and dispelling the myth that HCM risk markers are not useful predictors in young patients. [14] [15] [16] [17] [18] Notably, the European Society of Cardiology risk score model 42 proved highly ineffective 41 for identifying patients at the greatest SD risk. Notably, 7 of these 12 patients who died suddenly either declined an ICD even after receiving a standard formal recommendation for prophylactic device therapy, or were first evaluated in the 1990s, an era preceding ICD penetration into clinical HCM practice. 2 Furthermore, should these patients be hypothetically considered as likely survivors (with ICDs), the overall HCM mortality rate would be adjusted to 0.32%/y. Finally, 3 patients who died suddenly without apparent risk markers underscore the importance of completing the risk stratification algorithm in HCM. 36 In our study group, we found an excess of ICD implants in which 7 implants were necessary to generate one ICD that eventually intervened appropriately aborting ventricular tachycardia/ventricular fibrillation. Nevertheless, this ratio is somewhat lower than that reported in midlife HCM patients and similar to high-risk clinically compromised adult patients in randomized trials with coronary artery disease and systolic dysfunction after myocardial infarction, 49, 50 or in patients with nonischemic cardiomyopathy. 51 Also, we would expect that this rate of excess ICDs in HCM patients, and SD rates, as well, will decrease further with emerging advances in risk stratification, including use of contrast-enhanced cardiovascular magnetic resonance. 36 Nevertheless, the sizeable proportion of young patients with device complications cited here and elsewhere [1] [2] [3] [4] 20, 21, [24] [25] [26] [27] contributes to the ICD decision-making dilemma, 52 in which the preservation of life is weighed against the not insignificant potential for inappropriate shocks and lead-related problems over long periods of time. Indeed, the device complication rate of 26% reported here exceeds by 1.7-fold our appropriate ICD intervention rate of 15%. Most common among these complications are inappropriate shocks, which are, however, decreasing in frequency with the advantage of more sophisticated device management. This dilemma regarding ICD implants is particularly relevant in pediatric cardiology practice, and usually a matter best resolved by shared decision making. 1, 13, 20, 37 The reduction of SDs attributable to the penetration of the ICD into the HCM patient population [1] [2] [3] [9] [10] [11] [12] [13] 19, 20, 22 reported here has created a new paradigm in this disease for which advanced heart failure is emerging as the predominant mode of demise. 22, 29, 30 Indeed, even in this pediatric cohort, 11 patients had a clinical course in which early-onset progressive heart failure led to heart transplant before 25 years of age. Notably, ≈40% of these patients had preserved systolic function and >80% have survived to the present.
We believe that, by using current and advanced risk stratification and treatment strategies, 1, [9] [10] [11] [12] [13] 19, 20, 22, 23 we have demonstrated revised mortality risk for young patients with HCM in this referral-based population. Therefore, HCM clinical course and the expectation of longevity can be favorably altered for such patients presenting in the first 2 decades of life because of contemporary and largely nonpharmacological interventions such as ICDs. However, we should also underscore that the youth of patients in this cohort, some with aggressive early-onset disease, ultimately makes precise future predictions for longevity and quality of life more difficult than for an older adult population. 22 Comparisons of HCM-related outcome in the present pediatric patient group with those patients in a previously reported 1000 patient midlife adult cohort (presenting at 30-59 years of age) are relevant. 22, 23 Despite adverse event rates that were ≈2-fold greater in younger HCM patients (2.4%/y versus 1.3%/y in midlife), annual HCM mortality rates after major treatment interventions were virtually identical in each patient group (ie, 0.5%/y; Figure 5 ). This resulted because nonfatal HCM events aborted by contemporary treatment interventions were more common in pediatric patients by >2-fold (1.8%/y versus 0.8%/y). This observation underscores the life-saving potential and benefit of primary prevention ICDs, defibrillation and heart transplantation, and surgical septal myectomy, as well, to change the clinical course in these young HCM patients with the aspiration for many years of future productive life. Furthermore, such aggressive treatment can be expected to have even greater impact on the survival of young HCM patients than older adults.
It was not possible to assemble an untreated and rigidly matched control group to statistically address the reduced HCM-related mortality reported here. Nevertheless, it is an unavoidable clinical assertion that our high-risk patients could not have experienced longevity without the major treatment interventions employed here. It is also important to recognize that many patients in our cohort represent early-onset aggressive disease, probably not entirely representative of a theoretical general HCM population of children, adolescents, and young adults. Nevertheless, such a referral-based HCM patient population is well positioned to demonstrate the benefits of major treatment interventions when they are effectively applied to this age group. In conclusion, this longitudinally studied large hospitalbased cohort shows the potential for low mortality related to HCM in clinically identified young patients when contemporary treatment strategies and interventions are used (particularly ICDs). These interventions provide the opportunity to alter clinical course, extend longevity, and, in the process, preserve good quality of life. These data also alter the misconception that HCM in young patients is a uniformly progressive disease with limited management options.
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